SCHEMBL2733929

SCHEMBL2733929

c1cc2n(c1)CCCNC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.36
HTR2A P28223 6/20 0.36
ADRA2C P18825 1/20 0.36
KDM4E B2RXH2 2/20 0.33
CXCR4 P61073 2/20 0.33
MEN1 O00255 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30109 0.88
SCHEMBL28096141 0.86
Succinic Acid SCHEMBL9120466 0.74 TSHR (0.36) HTR2CHTR2AKDM4EMEN1TP53
SCHEMBL10152921 0.74
SCHEMBL1438685 0.70
SCHEMBL3022168 0.68 ALDH1A1 (0.35) CYP1A2CYP3A4CYP2D6MAPTCYP2C9
SCHEMBL22675658 0.68 CYBB (0.38) HTR2CHTR2AKDM4EMEN1TP53
SCHEMBL312640 0.67
SCHEMBL368146 0.67 CHRNB2 (0.35) CXCR4CHRNB2CHRNA4
SCHEMBL16102213 0.67 CHRNB2 (0.35) HTR2CHTR2ACXCR4CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200061072-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CERENIS THERAPEUTICS HOLDING SA (FR) 2020-02-27 US disclosed
US-10220040-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2019-03-05 US disclosed
CN-106167483-B It can be used for compound, composition and the method for cholesterol mobilization 塞伦尼斯医疗控股有限公司 2019-02-15 CN disclosed
US-20180064718-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION ABIONYX PHARMA (FR) 2018-03-08 US disclosed
EP-3241833-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION Cerenis Therapeutics Holding SA (FR) 2017-11-08 EP disclosed
US-9757381-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2017-09-12 US disclosed
CN-107011359-A Compound, composition and the method mobilized available for cholesterol 塞伦尼斯医疗控股有限公司 2017-08-04 CN disclosed
US-9713619-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2017-07-25 US disclosed
CN-103442714-B Compounds, compositions and methods useful for cholesterol mobilization 塞伦尼斯医疗控股有限公司 2017-04-19 CN disclosed
US-20160361318-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CERENIS THERAPEUTICS HOLDING SA (FR) 2016-12-15 US disclosed
CN-106167483-A Can be used for compound, compositions and method that cholesterol is mobilized 塞伦尼斯医疗控股有限公司 2016-11-30 CN disclosed
US-20150344455-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CERENIS THERAPEUTICS HOLDING SA (FR) 2015-12-03 US disclosed
US-9085585-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2015-07-21 US disclosed
US-20130267554-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CERENIS THERAPEUTICS HOLDING SA (FR) 2013-10-10 US disclosed
EP-2629776-A2 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION Cerenis Therapeutics Holding SA (FR) 2013-08-28 EP disclosed
US-8349833-B2 Compounds, compositions and methods useful for cholesterol mobilisation CERENIS THERAPEUTICS HOLDING SA (FR) 2013-01-08 US disclosed
US-20120129856-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION CERENIS THERAPEUTICS SA (FR) 2012-05-24 US disclosed
WO-2012054535-A2 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION CERENIS THERAPEUTICS SA (FR) 2012-04-26 WO disclosed
US-7202239-B2 Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists WYETH (US) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064718-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 HTR2C 4565/4885HTR2A 4463/4885ADRA2C 1633/4885
US-10220040-B2 Compounds, compositions and methods useful for cholesterol mobilization CETP, LIPA, NPC1L1 HTR2C 4565/4885HTR2A 4463/4885ADRA2C 1633/4885
US-20120129856-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION CETP, NPC1L1, NPC1 HTR2C 4395/4885HTR2A 4555/4885ADRA2C 1546/4885
US-20150344455-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 HTR2C 4565/4885HTR2A 4463/4885ADRA2C 1633/4885
US-20130267554-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 HTR2C 4565/4885HTR2A 4463/4885ADRA2C 1633/4885
US-20200061072-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 HTR2C 4565/4885HTR2A 4463/4885ADRA2C 1633/4885
US-20160361318-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 HTR2C 4565/4885HTR2A 4463/4885ADRA2C 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.